Professor Gerhardt Attard, UCL
Find out more
Professor Gerhard Attard received a PCR Project Award.
STAMPEDE: which drug will work best for me?
STAMPEDE is one of the largest ongoing clinical trials on advanced prostate cancer in the world, and has already led to changes in the way prostate cancer is treated. This latest research will look at DNA in tumors from men, who took part in STAMPEDE, and whose prostate cancer spread.
The team will see whether differences in DNA can be used to divide the men into groups which are more or less likely to respond to different treatments. By combining the results from this project with other research projects from STAMPEDE, they have a unique opportunity to develop an affordable test which could soon be used in the clinic to help doctors choose the right treatment for patients based on the specific profile of their individual cancer.
The Scientist Said...
“We have some very promising results on copy number profiling of a pilot set of 50 STAMPEDE tumors. PCR funding will enable us to expand our analyses to tumors from 675 men who received hormone therapy alone or with Abiraterone or Docetaxel and test the hypothesis that based on a cancer’s copy number profile, a decision on whether to use Abiraterone or docetaxel or no additional treatment can be made. This will be invaluable information for physicians and patients and allow us to implement precision medicine for these important treatments.” – Gerhardt Attard